Disinfection of the ocular mucosa.

• Prevention of bone complications (pathological fractures, spinal cord compression, bone irradiation or surgery, tumor-induced hypercalcemia) in adult patients with advanced malignant disease with bone involvement.
• Treatment of tumor-induced hypercalcemia (TIH) in adult patients.

• Prevention of bone complications (pathological fractures, spinal cord compression, bone irradiation or surgery, tumor-induced hypercalcemia) in adult patients with advanced malignant disease with bone involvement.
• Treatment of tumor-induced hypercalcemia (TIH) in adult patients.

Cisatracurium is an intermediate-acting non-depolarizing neuromuscular blocking agent for intravenous administration. CISATREX FORT is indicated during surgical procedures in adults and children aged 1 month and older. CISATREX FORT is also used in adults requiring intensive care. It can be used as an adjunct to general anesthesia or sedation in the Intensive Care Unit (ICU) to relax skeletal muscles, facilitate tracheal intubation and assisted ventilation.

Treatment of essential hypertension in patients whose blood pressure is not adequately controlled by losartan or hydrochlorothiazide monotherapy.

Treatment of essential hypertension in patients whose blood pressure is not adequately controlled by losartan or hydrochlorothiazide monotherapy.

Treatment of essential hypertension in patients whose blood pressure is not adequately controlled by losartan or hydrochlorothiazide monotherapy.

Treatment of essential hypertension in patients whose blood pressure is not adequately controlled by losartan or hydrochlorothiazide monotherapy.

Treatment of essential hypertension in patients whose blood pressure is not adequately controlled by losartan or hydrochlorothiazide monotherapy.

Treatment of essential hypertension in patients whose blood pressure is not adequately controlled by losartan or hydrochlorothiazide monotherapy.